TR200102514T2 - COPD tedavisi için metod - Google Patents

COPD tedavisi için metod

Info

Publication number
TR200102514T2
TR200102514T2 TR2001/02514T TR200102514T TR200102514T2 TR 200102514 T2 TR200102514 T2 TR 200102514T2 TR 2001/02514 T TR2001/02514 T TR 2001/02514T TR 200102514 T TR200102514 T TR 200102514T TR 200102514 T2 TR200102514 T2 TR 200102514T2
Authority
TR
Turkey
Prior art keywords
copd treatment
copd
treatment
pde
prophylaxis
Prior art date
Application number
TR2001/02514T
Other languages
English (en)
Inventor
B. Christensen Siegfried
S. Barnette Mary
J. Torphy Theodore
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200102514T2 publication Critical patent/TR200102514T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Bu bulus, belirli bir terapötik orani olan bir PDE 4 inhibitörünün uygulanmasi ile COPD profilaksisi veya tedavisi için bir metod ile ilgilidir.
TR2001/02514T 1999-03-01 2000-03-01 COPD tedavisi için metod TR200102514T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12231599P 1999-03-01 1999-03-01

Publications (1)

Publication Number Publication Date
TR200102514T2 true TR200102514T2 (tr) 2002-04-22

Family

ID=22401990

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02514T TR200102514T2 (tr) 1999-03-01 2000-03-01 COPD tedavisi için metod

Country Status (30)

Country Link
US (1) US6670394B1 (tr)
EP (1) EP1156799A4 (tr)
JP (1) JP2002538114A (tr)
KR (1) KR20010102459A (tr)
CN (1) CN1349403A (tr)
AP (1) AP2001002248A0 (tr)
AR (1) AR042369A1 (tr)
AU (1) AU772583B2 (tr)
BG (1) BG105953A (tr)
BR (1) BR0008603A (tr)
CA (1) CA2366036A1 (tr)
CO (1) CO5160248A1 (tr)
CZ (1) CZ20013149A3 (tr)
DZ (1) DZ3019A1 (tr)
EA (1) EA200100930A1 (tr)
HK (1) HK1043935A1 (tr)
HU (1) HUP0200288A3 (tr)
ID (1) ID29888A (tr)
IL (1) IL144992A0 (tr)
MA (1) MA25522A1 (tr)
NO (1) NO20014222L (tr)
NZ (1) NZ513695A (tr)
OA (1) OA11842A (tr)
PE (1) PE20001505A1 (tr)
PL (1) PL352816A1 (tr)
SK (1) SK12372001A3 (tr)
TR (1) TR200102514T2 (tr)
UY (1) UY26040A1 (tr)
WO (1) WO2000051598A1 (tr)
ZA (1) ZA200107186B (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
TW200512209A (en) * 2003-03-31 2005-04-01 Kyowa Hakko Kogyo Kk Treating and/or preventing agent for pulmonary diseases
WO2005056009A1 (ja) * 2003-12-12 2005-06-23 Kyowa Hakko Kogyo Co., Ltd. 肺疾患治療剤
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
CA2601250C (en) 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552438A (en) * 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
JP3251587B2 (ja) * 1992-04-02 2002-01-28 スミスクライン・ビーチャム・コーポレイション 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物
EP1466598A3 (en) 1993-06-18 2007-06-27 Smithkline Beecham Corporation PDE-IV inhibitors
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
CN1046274C (zh) * 1993-11-26 1999-11-10 辉瑞大药厂 用作消炎剂的异噁唑啉化合物
UY25338A1 (es) 1998-01-07 2001-08-27 Smithkline Beecham Corp Método para tratar copd

Also Published As

Publication number Publication date
KR20010102459A (ko) 2001-11-15
BG105953A (en) 2002-05-31
NO20014222L (no) 2001-10-29
IL144992A0 (en) 2002-06-30
HUP0200288A3 (en) 2003-08-28
CZ20013149A3 (cs) 2002-04-17
AU772583B2 (en) 2004-04-29
AP2001002248A0 (en) 2001-09-30
HUP0200288A2 (hu) 2002-05-29
NZ513695A (en) 2001-09-28
WO2000051598A1 (en) 2000-09-08
UY26040A1 (es) 2000-09-29
CN1349403A (zh) 2002-05-15
MA25522A1 (fr) 2002-10-01
ZA200107186B (en) 2002-08-30
CO5160248A1 (es) 2002-05-30
EP1156799A1 (en) 2001-11-28
JP2002538114A (ja) 2002-11-12
OA11842A (en) 2005-08-22
AR042369A1 (es) 2005-06-22
NO20014222D0 (no) 2001-08-31
BR0008603A (pt) 2001-12-26
US6670394B1 (en) 2003-12-30
PE20001505A1 (es) 2001-02-08
CA2366036A1 (en) 2000-09-08
EP1156799A4 (en) 2004-11-10
DZ3019A1 (fr) 2005-05-20
HK1043935A1 (zh) 2002-10-04
EA200100930A1 (ru) 2002-02-28
AU3386900A (en) 2000-09-21
SK12372001A3 (sk) 2001-12-03
ID29888A (id) 2001-10-18
PL352816A1 (en) 2003-09-08

Similar Documents

Publication Publication Date Title
BG106585A (en) Kinase inhibitors as therapeutic agents
ATE440603T1 (de) 8-hydroxychinolinderivate
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
HN2000000109A (es) Trifluorbutenos nematicidas
NO20021358L (no) Alkylendiamin-substituerte heterocykler
FI971489A (fi) Uusia bentsoksatsoleja
BR0109703A (pt) Derivados de piperazina
YU84603A (sh) Novi inhibitori tirozin kinaze
NO20003018D0 (no) Triazinangiogenese-inhibitorer
TR200102514T2 (tr) COPD tedavisi için metod
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
DE60318826D1 (de) Alkoxypyridinderivate
SE9802794D0 (sv) New compounds
NO20072060L (no) 2-acylaminotiazolderivater
SE9802793D0 (sv) New compounds
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
ATE305776T1 (de) Derivate von triterpen-säuren
HK1057886A1 (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
NO20030500D0 (no) Dihydroporfyrinderivater og deres anvendelse
PT1276722E (pt) Inibidores de naftamidina-uroquinase
DK1684763T3 (da) 6-Aryl-7-halogen-imidazo(1,2-a)pyrimidiner som anticancermiddel
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.
UA38786A (uk) Фібринолітичний засіб